News

Cleveland – September 30, 2026 -- Park Place Technologies has launched ParkView Asset Intelligence, an AI-powered platform that assigns every server, storage, network and security device a lifecycle health score from 0 to 100, giving IT managers OEM-level visibility to decide whether to refresh, repair or retire equipment.

Platform draws on 35 years of service data across nearly one million assets

Each score combines three data streams: Park Place's own hardware maintenance records spanning more than 35 years and roughly one million serviced assets across every major manufacturer, regional spare-parts availability, and a customer's own asset performance and service history. CEO Chris Adams said a device scoring 66 carries a different risk profile once IT teams see that comparable devices in the same model family average 92.

New York – September 30, 2026 -- ProphetX, described as America's first federally regulated sports-native prediction market, has signed a technology partnership with Plaee to give distribution operators a single integration point into its CFTC-regulated exchange, avoiding custom builds for each new partner.

Plaee's stack bundles trading, CRM and compliance access for operators

Through the deal, operators connect to ProphetX via Plaee's Prediction Trader, a white-label trading interface, and PlaeeOS, a CRM, personalization and monetization engine. Plaee says the setup lets operators add prediction markets to an existing product line or launch a standalone distribution channel within weeks using their current teams, rather than building exchange connectivity, liquidity access and regulatory infrastructure themselves.

Secaucus, N.J. – September 30, 2026 -- Pierre Fabre Pharmaceuticals Inc. (PFP) has resubmitted a Biologics License Application to the U.S. Food and Drug Administration for tabelecleucel, seeking approval as a monotherapy for adult and pediatric patients aged 2 and older with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed at least one prior therapy.

Resubmission follows April 2026 FDA alignment meeting

PFP filed the updated application after reaching agreement with the FDA during an April 2026 Type A meeting. The package includes an expanded dataset with additional patients and longer follow-up from the pivotal Phase 3 ALLELE study, which evaluates tabelecleucel in patients with EBV+ PTLD following hematopoietic cell transplant (HCT) or solid organ transplant (SOT).

Boston – – September 30, 2026 -- HFS Research has retired its flagship Horizons provider assessment and replaced it with HFS Services-as-SoftwareTM (SaS) Star Ratings, a scoring system built entirely on more than 400 enterprise client evaluations with zero vendor input and no analyst scoring.

The shift ends a model in which provider rankings were assembled from vendor briefings, RFI responses, and vendor-selected references before being scored by analysts. Under SaS Stars, providers cannot submit scoring inputs, buy inclusion, or select client references; only current enterprise clients who own or govern an engagement and have at least 12 months of experience with it are eligible to rate a provider.

Vancouver – – September 30, 2026 -- Silvercorp Metals Inc. (TSX: SVM) (NYSE American: SVM) has extended its shareholder proxy voting deadline to September 30, 2026 at 4:00 p.m. Pacific time, after approving a further revision to a special resolution governing amendments to the Company's corporate Articles ahead of its annual general and special meeting scheduled for October 2, 2026.

Company narrows information it can demand from director nominees

Silvercorp has amended Article 16, which governs how shareholders nominate individuals for election to the Board. Having initially proposed limiting the information required to assess a nominee's independence, the Company has now gone further, removing its ability to request any nominee information beyond items specifically enumerated in Article 16, paragraph 4. A redline of the proposed changes was filed on SEDAR+ on September 29, 2026 under "Other Securityholder Documents."

Brookfield, Wis. – September 30, 2026 -- Milwaukee Tool has joined the Alliance for America's Skilled Trades and projects its cumulative U.S. workforce development investment will exceed $200 million by 2030, based on spending since 2010 and plans through the decade's end.

Milwaukee Tool backs more than 16,000 apprentices annually across the country

The company currently supports over 16,000 apprentices enrolled in skilled trades programs, working with more than 1,300 training centers and 25 national union and non-union partners nationwide.

Frisco, Texas – September 30, 2026 -- Thirty-one percent of healthcare organizations experienced unauthorized identities accessing sensitive data in the past year, compared with 24% across other industries, according to new healthcare findings from Netwrix's 2026 Data and Identity Security Report. Among healthcare organizations that suffered an incident, 33% reported costs exceeding $250,000, versus 21% in other sectors.

Healthcare ranks last among 16 industries on Active Directory confidence

Only 14% of healthcare organizations said they are fully confident their Active Directory environments are free of privilege escalation risks, compared with 26% across all industries surveyed. Eighty-six percent lack full confidence in their AD security, the lowest ranking among the 16 industries with sufficient survey representation for comparison.

Cleveland – September 30, 2026 -- Arrowfly has launched AI for Engineers, a year-round platform combining a dedicated news desk, an annual conference, original research, and an advisory board for engineers applying artificial intelligence across design, manufacturing, robotics, medtech, and energy work.

Arrowfly taps a 2.1 million-reader network to anchor the new initiative

The program draws on Arrowfly's more than 20 flagship engineering brands, which collectively reach 2.1 million verified industry readers, 29 million website visitors, 1.6 million email subscribers, and generate 202 million monthly impressions. More than 30,000 engineering and technical professionals have already engaged with AI-related webinars, newsletters, and editorial content across Arrowfly's engineering portfolio.

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) said its EBGLYSS (lebrikizumab-lbkz) monotherapy met the primary and secondary endpoints of the Phase 3b ADtouch study at Week 16, with more than half of treated patients achieving clear or almost clear skin on hands and feet (HF-IGA 0/1), the company disclosed ahead of the European Academy of Dermatology and Venereology Congress in Vienna, running Sept. 30-Oct. 3.

Trial enrolled 221 patients with moderate-to-severe hand and foot atopic dermatitis

The randomized, double-blind, placebo-controlled ADtouch trial (NCT06921759) assigned 221 adults and adolescents 1:1 to EBGLYSS 250 mg or placebo every two weeks over 16 weeks, following an initial loading dose. Participants had an inadequate response to topical therapies and applied moisturizer throughout the study.

Itasca, Illinois – September 30, 2026 -- Knowles Corporation (NYSE:KN) has introduced its new ATT A-Series Attenuators, expanding its RF portfolio to position the company as a one-stop source for high-performance RF signal chain components.

New attenuators deliver DC-20 GHz coverage in a compact SMT package

The A-Series uses precision thin-film resistor technology on a ceramic substrate, measuring just 0.080" x 0.065" x 0.012" (2.03 x 1.65 x 0.30 mm). The product line offers standard attenuation values from 0 dB to 20 dB with a power handling rating up to 6.5 W CW at 100°C and an operating temperature range of -55°C to +125°C.